Showing results (1-10 of 129) with videos related to
Sort By:
Pageof 13
Kidney International Reports|June 11, 2020
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKDRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.Kidney International Reports|June 11, 2020
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan FormulationsRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2017
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life InstrumentDorothee Oberdhan, Jason C Cole, Holly B Krasa, et al.American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.The New England Journal of Medicine|November 6, 2012
Tolvaptan in patients with autosomal dominant polycystic kidney diseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.Kidney International Reports|November 17, 2017
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseRonald D Perrone, Mohamad-Samer Mouksassi, Klaus Romero, et al.Kidney International Reports|November 17, 2017
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney DiseaseRonald D Perrone, Mohamad-Samer Mouksassi, Klaus Romero, et al.Pageof 13